Developing selective small-molecule inhibitors of

The National Institutes of Health, Office of Acquisitions, seeks to award a firm-fixed-price contract for pharmacokinetic and pharmacodynamic studies of three NNMT inhibitor compounds in mice, with proposals due August 24, 2026. This is an unrestricted, full and open competition for commercial products or services under FAR 12.603.

Place of performance is not specified; results are to be delivered to NCATS within three months of purchase order receipt. The work requires monitoring plasma concentrations of parent drug and metabolite (1-MNA) at ten predetermined time points (0, 5, 15, 30 minutes, 1, 2, 4, 8, 12, and 24 hours post-dose) with n=3 mice per time point, and delivering concentration versus time curves and pharmacokinetic parameters in an Excel report. The Government will provide the three NNMT inhibitor compounds. Period of performance runs September 4, 2026 through March 3, 2027. Estimated level of effort is one PhD-level manager and one PhD-level scientist for three months total. The NAICS code is 541715, Research and Development in the Physical, Engineering, and Life Sciences, with a small business size standard of 1,000 employees. PSC code is Q301, Reference Laboratory Testing. Evaluation factors are price, technical capability, past performance, and delivery schedule. All responses must include unit and total price, shipping and handling costs, delivery timeframe and terms, F.O.B. point, product description, UEI, TIN, and business size certification. Submit electronically to Jaddua.Johnston@nih.gov. Point of contact is Jaddua Johnston, Contracting Specialist, 240-569-0006. Delivery to Samarjit Patnaik (samarjit.patnaik@nih.gov) and Vinoth Chenniappan (vinothkumar.chenniappan@nih.gov).